BVF I GP LLC

BVF I GP LLC has an estimated net worth of $611 Million. This is based on reported shares across multiple companies, which include Allakos Inc., Rain Oncology Inc., Cullinan Oncology, Inc., Repare Therapeutics Inc., Verastem, Inc., IDEAYA Biosciences, Inc., CYTOKINETICS INC, Kymera Therapeutics, Inc., Merus N.V., CytomX Therapeutics, Inc., MoonLake Immunotherapeutics, Principia Biopharma Inc., Eledon Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., XOMA Royalty Corp, CTI BIOPHARMA CORP, ESSA Pharma Inc., 4D Molecular Therapeutics, Inc., PALVELLA THERAPEUTICS, INC., Third Harmonic Bio, Inc., FIVE PRIME THERAPEUTICS, INC., Structure Therapeutics Inc., enGene Holdings Inc., POINT Biopharma Global Inc., GLYCOMIMETICS INC, INFINITY PHARMACEUTICALS, INC., and IMMUNIC, INC..

2020 was BVF I GP LLC's most active year for acquiring shares with 116 total transactions. BVF I GP LLC's most active month to acquire stocks was the month of April. 2020 was BVF I GP LLC's most active year for disposing of shares, totalling 33 transactions. BVF I GP LLC's most active month to dispose stocks was the month of December. 2021 saw BVF I GP LLC paying a total of $132,144,944.64 for 12,405,370 shares, this is the most they've acquired in one year. In 2023 BVF I GP LLC cashed out on 40,301,603 shares for a total of $294,248,967.10, their largest year based on trade value.